.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This long-term extension study evaluated the durability of ublituximab treatment in adults with relapsing multiple sclerosis who had completed the phase 3 ULTIMATE I and II trials. Of 985 participants completing the original studies, 851 entered the extension. Participants who switched from teriflunomide to ublituximab experienced a 58.4% reduction in annualized relapse rate during the first year after switching, from 0.182 to 0.076 (rate ratio, 0.42; 95% CI, 0.29–0.60; \(p<0.001\)). Among participants who received ublituximab continuously, the annualized relapse rate decreased to 0.020 by year five. At year five, 8.0% of continuously treated participants had 24-week-confirmed disability progression compared with 14.3% of those who initially received teriflunomide before switching (\(p=0.01\)). The safety profile remained consistent with previous trials. Although the findings support sustained disease control, the open-label extension and attrition limit direct causal comparisons between treatment groups.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This long-term extension study evaluated the durability of ublituximab treatment in adults with relapsing multiple sclerosis who had completed the phase 3 ULTIMATE I and II trials. Of 985 participants completing the original studies, 851 entered the extension. Participants who switched from teriflunomide to ublituximab experienced a 58.4% reduction in annualized relapse rate during the first year after switching, from 0.182 to 0.076 (rate ratio, 0.42; 95% CI, 0.29–0.60; \(p<0.001\)). Among participants who received ublituximab continuously, the annualized relapse rate decreased to 0.020 by year five. At year five, 8.0% of continuously treated participants had 24-week-confirmed disability progression compared with 14.3% of those who initially received teriflunomide before switching (\(p=0.01\)). The safety profile remained consistent with previous trials. Although the findings support sustained disease control, the open-label extension and attrition limit direct causal comparisons between treatment groups.
Today
A retrospective CAHAL study comparing Amplatzer and Occlutech devices in 413 patients found no significant difference in moderate-to-large residual shunt rates at 6 months follow-up after percutaneous PFO closure, supporting clinical equivalence between both platforms.
Today
AIIMS researchers suggest yoga may alleviate gut dysbiosis in Polyendocrine Metabolic Ovarian Syndrome (PMOS) by modulating the gut-brain axis, lowering chronic inflammation, and enhancing parasympathetic tone to support metabolic and hormonal equilibrium.
Today
A structured practical guide to left atrial echocardiographic assessment covering biplane volumetry, phasic physiology, speckle-tracking strain, and hemodynamic filling pressure estimation for routine cardiovascular practice.
Today
Age-related spinal kyphosis is driven by vertebral fragility, disc degeneration, and paraspinal muscle dysfunction. Coexisting with locomotive syndrome and frailty, its management requires combined anti-osteoporotic therapy, spinal extensor rehabilitation, and comprehensive nutritional optimization.
Today
A longitudinal feasibility pilot study highlights that combining polygenic risk score disclosure with in-person lifestyle counseling significantly enhances genomic literacy in individuals at risk for type 2 diabetes, overcoming educational disparities and reinforcing patient motivation.
Today
